BCR and leukemia: In human leukemias, the enhancement of the oncogenic activity of Abl is mediated by chromosomal translocation [t(9;22) (q34;q11)] to generate BCR-ABL1 fusion proteins, leading to the disruption of intramolecular interactions of inhibitory Abl1 [230].